Since February 19, Iran has also been one of the countries in the Middle East region where the spread of COVID-19 started. Following the outbreak of coronavirus 2019 in Iran, quarantine began in various cities across Iran, according to the National Headquarters of Coronavirus Disease Management. Imposing quarantine in red cities of Iran has helped to curb the spread of the disease. Over the past few months, the quarantine and the full following of protocols by people have slowed down the progress of coronavirus in Iran. 

Coronavirus 2019 inflames the cells lining the arteries, causing blood to clot inside the arteries. This is one of the serious problems that doctors face in treating patients with COVID-19. For this reason, anticoagulant drugs were introduced and implemented in Iran’s treatment protocol. Moreover, the level of ” D-dimer ” in patients will be tested by the physician to give a dose for the prevention or treatment. This action can reduce the mortality rate from blood clots in the lungs by 30% in patients with COVID-19in Iran. Based on the reports published by Iran’s National Headquarters of Coronavirus Disease Management, the recommended drugs which have been prescribed for the treatment of Covid-19 have been able to shorten the length of hospitalization in affected patients.  However, more patients need to be tested. Recently, a drug called “Favipiravir” was used in Iran, which did not have a functional advantage over “Kaletra” and was therefore removed from the treatment protocol.

In recent months, the news of the positive results of an antiviral drug “Remdesivir “in the United States raised hopes for the treatment of Covid-19. After the news of its successful outcome, the Food and Drug Administration (FDA) authorized the emergency use of the drug. Following the approval of “Remdesivir ” by FDA, Iran included the use of this drug in the treatment protocol. “Remdesivir ” is an injectable drug. According to doctors, the patient must be hospitalized for up to 10 days, when the drug is administered. Other anti-inflammatory drugs that reduce lung inflammation are also included in the treatment protocol for patients with COVID-19.

The body’s immune defense system and resistance is a vital factor in tackling COVID-19. Consequently, patients with underlying conditions, such as high blood pressure, heart disease, and diabetes, are at risk. These people are more susceptible to becoming infected with COVID-19 due to their weak immune system. While eighty percent of patients have mild symptoms, the range of symptoms of COVID-19 varies extensively. Patients who have severe lung inflammation and low blood oxygen and radiological signs indicate that lung is involved need immediate hospitalization. In cases where there is no shortness of breath, and the patient has a mild range of symptoms, it is recommended that patients remain and rest at home and take prescribed medications.